MicroRNAs as active players in the pathogenesis of Multiple Sclerosis

International Journal of Molecular Sciences

Volumn 13, Issue 10, 2012, Pages 13227-13239

  Fenoglio, Chiara ^a   Ridolfi, Elisa ^a   Galimberti, Daniela ^a   Scarpini, Elio ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Biomarker; Central nervous system; Immune system; MicroRNA; Multiple sclerosis

Indexed keywords

BETA INTERFERON; GLATIRAMER; MICRORNA; MICRORNA 155; MICRORNA 223; MICRORNA 326; NATALIZUMAB; RNA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CYTOKINE; IMMUNOSUPPRESSIVE AGENT;

B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; BRAIN DAMAGE; CD4+ T LYMPHOCYTE; DRUG EFFECT; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE FUNCTION; GENE INTERACTION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEMATOLOGIC DISEASE; HUMAN; IMMUNE RESPONSE; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION; CENTRAL NERVOUS SYSTEM; GENETICS; IMMUNE SYSTEM; METABOLISM; PATHOLOGY;

BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM; CYTOKINES; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; MICRORNAS; MULTIPLE SCLEROSIS;

EID: 84867832050     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms131013227     Document Type: Review

References (61)

1. Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281-297.
2. Tufekchi, K.U.; Oner, M.G.; Genc, S.; Genc, K. MicroRNAs and multiple sclerosis. Autoimmune Diseases 2011, doi:10.4061/2011/807426.
3. Ha, T-Y. The role of microRNAs in regulatory T cells and the immune response. Immune Network 2011, 11, 11-41.
4. Lages, E.; Ipas, H.; Guttin, A.; Houssan, N.; Berger, F.; Issartel, J.P. MicroRNAs: Molecular features and role in cancer. Front. Biosci. 2012, 17, 2508-2540.
5. O'Connell, R.M.; Rao, D.S.; Chaudhuri, A.A.; Baltimore, D. Physiological and pathological roles for microRNAs in the immune system. Nat. Rev. Immunol. 2010, 10, 111-122.
6. Compston, A.; Coles, A. Multiple sclerosis. Lancet 2008, 372, 1502-1517.
7. Ireland, S.; Monson, N. Potential impact of B cells and T cell function in multiple sclerosis. Mult. Scler. Int. 2011, 2011, doi:10.1155/2011/423971.
8. Miller, A.E. Multiple sclerosis: Where will be in 2020? Mt. Sinai J. Med. 2011, 78, 268-279.
9. Stys, P.K.; Zamponi, G.W.; van Minnen, J.; Geurts, J.J.G. Will the real multiple sclerosis stand up? Nat. Rev. Immunol. 2012, 13, 507-514.
10. Liston, A.; Linterman, M.; Lu, L-F. MicroRNA in the adaptive immune system, in sickness and in health. J. Clin. Immunol. 2010, 30, 339-346.
11. Tesmer, L.A.; Lundy, S.K.; Sarkar, S.; Fox, D.A. Th17 cells in human disease. Immunol. Rev. 2008, 223, 87-113.
12. Du, C.; Liu, C.; Kang, J.; Zhao, G.; Ye, Z.; Huang, S.; Li, Z.; Wu, Z.; Pei, G. MicroRNA miR-326 regulates Th-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat. Immunol. 2009, 10, 1252-1259.
13. Xiao, C.; Srinivasan, L.; Calado, D.P.; Patterson, H.C.; Zhang, B.; Wang, J.; Henderson, J.M. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat. Immunol. 2008, 9, 405-414.
14. Juntilla, M.M.; Koretzky, G.A. Critical roles of the PI3K/Akt signaling pathway in T cell development. Immunol. Lett. 2008, 116, 104-110.
15. Ovcharenco, D.; Kelnar, K.; Johnson, C.; Leng, N.; Brown, D. Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res. 2007, 67, 10782-10788.
16. Lindberg, R.L.P.; Hoffmann, F.; Mehling, M.; Kuhle, J.; Kappos, L. Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. Eur. J. Immunol. 2010, 40, 888-898.
17. Tang, Q.; Bluestone, J.A. Regulatory T cell physiology and application to treat autoimmunity. Immunol. Rev. 2006, 212, 217-237.
18. Petrocca, F.; Vecchione, A.; Croce, C.M. Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res. 2008, 68, 8191-8194.
19. De Santis, G.; Ferracin, M.; Biondani, A.; Caniatti, L.; Tola, M.A.; Castellezzi, M.; Zagatti, B.; Battistini, L.; Borsellino, G.; Fainardi, E.; et al. Altered miRNA expression in T regulatory cells in course of multiple sclerosis. J. Neuroimmnuol. 2010, 226, 165-171.
20. Guerau-de-Arellano, M.; Smith, K.M.; Godlewski, J.; Liu, Y.; Winger, R.; Lawler, S.E.; Whitacre, C.C.; Racke, M.K.; Lovett-Racke, A.E. Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity. Brain 2011, 134, 3578-3589.
21. Otaegui, D.; Baranzini, S.E.; Armañanzas, R.; Calvo, B.; Muñoz-Culla, M.; Khankhanian, P.; Inza, I.; Lozano, J.A.; Castillo-Triviño, T.; Asensio, A.; et al. Differential micro RNA expression in PBMC from multiple sclerosis patients. PLoS One 2009, 4, doi:10.1371/journal.pone.0006309.
22. Fenoglio, C.; Cantoni, C.; de Riz, M.; Ridolfi, E.; Cortini, F.; Sepente, M.; Villa, C.; Comi, C.; Monaco, F.; Mellesi, L.; et al. Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis. Neurosci. Lett. 2011, 504, 9-12.
23. Martinelli-Boneschi, F.; Fenoglio, C.; Brambilla, P.; Sorosina, M.; Giacalone, G.; Esposito, F.; Serpente, M.; Cantoni, C.; Ridolfi, E.; Rodegher, M.; et al. MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. Neurosci. Lett. 2012, 508, 4-8.
24. Keller, A.; Leidinger, P.; Lange, J.; Borries, A.; Schroers, H.; Scheffler, M.; Lenhof, H.P.; Ruprecht, K.; Meese, E. Multiple sclerosis: MicroRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS One 2009, 4, doi:10.1371/journal.pone.0007440.
25. Cox, M.B.; Cairns, M.J.; Gandhi, K.S.; Carroll, A.P.; Moscovis, S.; Stewart, G.J.; Broadley, S.; Scott, R.J.; Booth, D.R.; Lechner-Scott, J. ANZgene Multiple Sclerosis Genetics Consortium. MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood. PLoS One 2010, 5, doi:10.1371/journal.pone.0012132.
26. Junker, A.; Krumbholz, M.; Eisele, S.; Mohan, H.; Augstein, F.; Bittner, R.; Lassmann, H.; Wekerle, H.; Hohlfeld, R.; Meinl, E. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 2009, 132, 3342-3352.
27. Hanke, M.; Hoefig, K.; Merz, H.; Feller, A.C.; Kausch, I. A robust methodology to study urine microRNA as tumor marker: MicroRNA-126 and microRNA-182 are related tourinary bladder cancer. Urol. Oncol. 2010, 28, 655-661.
28. Park, N.J.; Zhou, H.; Elashoff, D.; Henson, B.S.; Kastratovic, D.A. Salivary microRNA: Discovery, characterization, and clinical utility for oral cancer detection. Clin. Cancer Res. 2009, 15, 5473-5477.
29. Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O'Briant, K.C.; Allen, A.; et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513-10518.
30. Redell, J.B.; Moore, A.N.; Ward, N.H., III; Hergenroeder, G.W.; Dash, P.K. Human traumatic brain injury alters plasma microRNA levels. J. Neurotrauma 2009, 27, 2147-2156.
31. Boeri, M.; Verri, C.; Conte, D.; Roz, L.; Modena, P. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc. Natl. Acad. Sci. USA 2011, 108, 3713-3718.
32. Siegel, S.R.; Mackenzie, J.; Chaplin, G.; Jablonski, N.G.; Griffiths, L. Circulating microRNAs involved in multiple sclerosis. Mol. Biol. Rep. 2012, 39, 6219-6225.
33. Fenoglio, C.; Ridolfi, E.; Serpente, M.; Cantoni, C.; de Riz, M.; Pietroboni, A.; Villa, C.; Cortini, F.; Piccio, L.; Bresolin, N.; et al. Cell-free microRNA and multiple sclerosis: Possible promising biomarkers? Mult. Scler. 2011, 17, S53-S276.
34. Clemente, D.; Ortega, M.C.; Arenzana, F.J.; de Castro, F. FGF-2 and Anosmin-1 are selectively expressed in different types of multiple sclerosis lesions. J. Neurosci. 2011, 31, 14899-14909.
35. Sarchielli, P.; di Filippo, M.; Ercolani, M.V.; Chiasserini, D.; Mattioni, A. Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patients. Neurosci. Lett. 2008, 435, 223-228.
36. Aulchenko, Y.S.; Hoppenbrouwers, I.A.; Ramagopalan, S.V.; Broer, L.; Jafari, N. Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis. Nat Genet. 2008, 40, 1402-1403.
37. Lyons, D.A.; Naylor, S.G.; Scholze, A.; Talbot, W.S. Kif1b is essential for mRNA localization in oligodendrocytes and development of myelinated axons. Nat. Genet. 2009, 41, 854-858.
38. Martinelli-Boneschi, F.; Esposito, F.; Scalabrini, D.; Fenoglio, C.; Rodegher, M.E. Lack of replication of KIF1B gene in an Italian primary progressive multiple sclerosis cohort. Eur. J. Neurol. 2010, 17, 740-745.
39. Goris, A.; Boonen, S.; D'hooghe, M.B.; Dubois, B. Replication of KIF21B as a susceptibility locus for multiple sclerosis. J. Med. Genet. 2010, 47, 775-776.
40. Koutsis, G.; Karadima, G.; Floroskufi, P.; Sfagos, C.; Vassilopoulos, D.; Panas, M. The rs10492972 KIF1B polymorphism and disease progression in Greek patients with multiple sclerosis. J. Neurol. 2011, 258, 1726-1728.
41. Sombekke, M.H.; Jafari, N.; Bendfeldt, K.; Mueller-Lenke, N.; Radue, E.W. No influence of KIF1B on neurodegenerative markers in multiple sclerosis. Neurology 2011, 76, 1843-1845.
42. Kudryavtseva, E.A.; Rozhdestvenskii, A.S.; Kakulya, A.V.; Khanokh, E.V.; Delov, R.A. Polymorphic locus rs10492972 of the KIF1B gene association with multiple sclerosis in Russia: Case control study. Mol. Genet. Metab. 2011, 104, 390-394.
43. Nowakowska, B.A.; Obersztyn, E.; Szymańska, K.; Bekiesińska-Figatowska, M.; Xia, Z. Severe mental retardation, seizures, and hypotonia due to deletions of MEF2C. Am. J. Med. Genet. Part B 2010, 153, 1042-1051.
44. Li, T.; Morgan, M.J.; Choksi, S.; Zhang, Y.; Kim, Y.S.; Liu, Z.G. MicroRNAs modulate the noncanonical transcription factor NF-κB pathway by regulating expression of the kinase IKKα during macrophage differentiation. Nat. Immunol. 2010, 11, 799-805.
45. Fulci, V.; Scappucci, G.; Sebastiani, G.D.; Giannitti, C.; Franceschini, D. miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis. Hum. Immunol. 2010, 71, 206-211.
46. Hoppenbrouwers, I.A.; Hintzen, R. Genetics of multiple sclerosis. Biochim. Biophys. Acta 2011, 1812, 194-201.
47. Gourraud, P.A.; Harbo, H.F.; Hauser, S.L.; Baranzini, S.E. The genetics of multiple sclerosis: An up-to-date review. Immunol. Rev. 2012, 248, 87-103.
48. Salzman, D.W.; Weidhaas, J.B. SNPing cancer in the bud: MicroRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer. Pharmacol. Ther. 2012, in press.
49. Paraboschi, E.M.; Soldà, G.; Gemmati, D.; Orioli, E.; Zeri, G.; Benedetti, M.D.; Salviati, A.; Barizzone, N.; Leone, M.; Duga, S.; et al. Genetic association and altered gene expression of miR-155 in multiple sclerosis patients. Int. J. Mol. Sci. 2011, 12, 8695-8712.
50. Sonkoly, E.; Wei, T.; Janson, P.C.; Saaf, A.; Lundeberg, L.; Tengvall-Linder, M.; Norstedt, G.; Alenius, H.; Homey, B.; Scheynius, A.; et al. MicroRNAs: Novel regulators involved in the pathogenesis of psoriasias? PLoS One 2007, 2, doi:10.1371/journal.pone.0000610.
51. Cobb, B.S.; Hertweck, A.; Smith, J.; O'Connor, E.; Graf, D.; Cook, T.; Smale, S.T.; Sakaguchi, S.; Livesey, F.J.; Fisher, A.G.; et al. A role for Dicer in immune regulation. J. Exp. Med. 2006, 203, 2519-2527.
52. Murugaiyan, G.; Beynon, V.; Mittal, A.; Joller, N.; Weiner, H.L. Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 2011, 187, 2213-2221.
53. Czech, M. MicroRNAs as therapeutic targets. N. Engl. J. Med. 2006, 354, 1194-1195.
54. Krützfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K.G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of microRNAs in vivo with "antagomirs". Nature 2005, 438, 685-689.
55. Im, H.I.; Kenny, P.J. MicroRNAs in neuronal function and dysfunction. Trends Neurosci. 2012, 35, 325-334.
56. Li, Y.; He, C.; Jin, P. Emergence of chemical biology approaches to the RNAi/miRNA pathway. Chem. Biol. 2010, 17, 584-589.
57. Watashi, K. Identification of small molecules that suppress microRNA function and reverse tumorigenesis. J. Biol. Chem. 2010, 285, 24707-24716.
58. Steinman, L. A rush to judgment on Th17. J. Exp. Med. 2008, 205, 1517-1522.
59. Tzartos, J.S.; Friese, M.A.; Craner, M.J.; Palace, J.; Newcombe, J.; Esiri, M.M.; Fugger, L. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 2008, 172, 146-155.
60. Waschbisch, A.; Atiya, M.; Linker, R.A.; Potapov, S.; Schwab, S.; Derfuss, T. Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. PLoS One 2011, 6, doi:10.1371/journal.pone.0024604.
61. Sievers, C.; Meira, M.; Hoffmann, F.; Fontoura, P.; Kappos, L.; Lindberg, R.L. Altered microRNA expression in B lymphocytes in multiple sclerosis: Towards a better understanding of treatment effects. Clin. Immunol. 2012, 144, 70-79.